Repligen Corporation (RGEN) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Instruments & Supplies secteur d'activité. Le siège social de l'entreprise est situé à Waltham, MA, United States. Le PDG actuel est Olivier Loeillot.
RGEN a date d'introduction en bourse 1986-04-29, 1,778 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $7.38B.
Repligen Corporation is a global bioprocessing technology company that develops and commercializes systems and products for biological drug manufacturing. The company serves biopharmaceutical, life sciences, and diagnostics customers across North America, Europe, and Asia Pacific with a comprehensive portfolio including Protein A affinity chromatography resins, pre-packed chromatography columns, cell culture growth factors, filtration systems, and process analytics solutions. Its product lines—such as OPUS chromatography columns, XCell filtration systems, and SoloVPE spectroscopy platforms—support critical stages of biologic drug purification, concentration, and quality control. Repligen was founded in 1981 and is headquartered in Waltham, Massachusetts.
